Skip to content
Screener

Ionis Pharmaceuticals IONS Total costs & expenses

Total costs & expenses at other companies

BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$119.79M-10.3%
ALN
Alnylam PharmaceuticalsALNY
$1.06B+34.1%
Intellia Therapeutics logo
Intellia TherapeuticsNTLA
$120.42M-3.1%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$300.47M+36.0%
Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
$34.35M-57.9%

Other financials

Income statement

See full
Revenue$267.9M-40.7%
Gross profit$265.2M-40.8%
Operating income-$102.3M-173%
Net income-$114.6M-193%
EPS (diluted)-$0.69-199%

Balance sheet

See full
Cash & equivalents$350.1M+17.7%
Total debt$262.5M-67.0%
Total equity$439.7M-30.4%
Total assets$3.0B+0.3%

Cash flow

See full
Operating cash flow-$792.8M-426%
CapEx$16.1M+30.7%
Free cash flow-$814.6M-399%

Valuation

See full
Market cap$9.01B+38.9%
Enterprise value$8.92B+27.7%
P/S10.3×+3.4×

Profitability

See full
Gross margin98.2%-0.7pp
Operating margin-68%-234pp
Net margin-64.7%-299pp
FCF margin-77.4%+35.3pp

Returns & leverage

See full
Return on equity-105.5%+336pp
Debt / equity0.6×-0.7×
Current ratio7.9×+5.0×

Where this comes from

Reported directly by Ionis Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:CostsAndExpenses.

The source filing: Ionis Pharmaceuticals’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 5:05 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000874015-26-000251
Line itemThree Months Ended / June 30, 2026Three Months Ended / June 30, 2025Six Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Cost of sales2,7394,1515,7215,614
Research, development and patent217,107217,460427,280418,219
Selling, general and administrative150,39690,622300,755166,872
Total operating expenses370,242312,233733,756590,705
Income (loss) from operations(102,293)139,816(219,714)(7,045)
Other income (expense):
Investment income20,23024,68745,71349,354
Interest expense(4,618)(4,114)(9,778)(8,223)

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Ionis Pharmaceuticals's total costs & expenses?
Ionis Pharmaceuticals (IONS) reported total costs & expenses of $370.24M in Q2 2026.
How has Ionis Pharmaceuticals's total costs & expenses changed year-over-year?
Ionis Pharmaceuticals's total costs & expenses increased by 18.6% year-over-year, from $312.23M to $370.24M.
What is the long-term trend for Ionis Pharmaceuticals's total costs & expenses?
Over 4 years (2021 to 2025), Ionis Pharmaceuticals's total costs & expenses has grown at a 12.1% compound annual growth rate (CAGR), from $840.64M to $1.33B.
What does total costs & expenses mean?
The aggregate of all operating and non-operating costs incurred during the reporting period. This provides a comprehensive view of the total resource consumption required to sustain business operations.

Ask your AI about Ionis Pharmaceuticals's total costs & expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude